Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document): Heather Brody (Creator); Anushi Bulumulle (Creator); Cynthia R. Cherry (Creator); Daniel B. Costa (Creator); Ritu R. Gill (Creator); Mark S. Huberman (Creator); Shravanti Macherla (Creator); Danielle C. McDonald (Creator); Aleksandra Qilleri (Creator); Deepa Rangachari (Creator); Kartik Sehgal (Creator); Meghan Shea (Creator); Paul A. VanderLaan (Creator); Paul R. Walker (Creator); Glen J. Weiss (Creator)
Institution: East Carolina University (ECU ); Web Site: http://www.ecu.edu/lib/

Additional Information

Publication: Other; Language: English; Date: 2023
Subjects: Extended-interval dosing;Immune-related adverse event;Patient-physician preference

Email this document to

This item references:

Title	Location & Link	Type of Relationship
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer	http://hdl.handle.net/10342/11327	The described resource references, cites, or otherwise points to the related resource.